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Abstract  Tuberculosis (TB) is an infectious fatal disease mainly among the developing countries. It is caused by 
a bacterium called Mycobacterium tuberculosis and spreads through the air and infects the lungs and other organs 
and parts of the persons who come in contact to the infected persons. It remains a major global health problem and 
about 2 billion people are thought to be infected with TB and about 1.3 million died each year from the disease. In 
the 95% of all cases, 99% of death occurs in developing countries, with the greatest burden in Sub-Saharan Africa 
and Southeast Asia. India alone accounts for an estimated one-quarter (26%) of all TB cases worldwide and only 
China and India combine accounting for 38%. To prevent TB, the WHO recommends that infants receive a BCG 
vaccine where TB is a common disease. At present each year globally about 100 million children receive BCG 
vaccine. Drug resistant TB is a rising global problem which is more difficult and expensive to treat and cure or 
sometimes it is impossible to treat successfully. It can occur when healthcare providers prescribe the wrong 
treatment, the wrong dose, or wrong length of time for taking the drugs or irregular and incomplete medicines are 
used by the patients.  
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1. Introduction 
 
       Tuberculosis (TB) is a contagious chronic 
bacterial infection. It is curable and preventable 
disease. It spreads through the air and infects the 
lungs and other organs and parts of the human body 
(about 15% patients) such as, the lymph nodes, the 
urinary tract and the abdomen, bones, brain, the 
kidneys, spine and even the skin. A person needs to 
inhale only a few of these germs to become infected. 
From the lungs, TB bacteria move through the blood 
to the different parts of the body. In people who 
develop active TB of the lungs called pulmonary TB 
[47]. Among people suffering from TB disease, 3 out 
of 4 have disease affecting the lungs. Between 2 to 8 
weeks after being infected person’s immune system 
responds to the TB germ by walling off infected 
cells. If not treated immediately, the bacteria have the 
potential to destroy the lungs and kill the person. It is 
usually treated with a schedule of drugs taken for 6 
months to 2 years, depending on the type of infection. 
Most people undergo complete healing of their initial 
infection, and the bacteria eventually die off. TB 
infections in the world began to increasing since 
1980s, because of the appearance of HIV. The reason 
is HIV weakens a person’s immune system, so it 
cannot fight the TB germs. TB and HIV have a strong 
fatal correlation; each drives the progress of the 
other. Worldwide, TB is one of the leading causes of 
death among people living with HIV. A person who 
has both HIV infection and TB disease has an AIDS-
defining condition. People with weakened immune 
systems, at a greater risk for developing TB disease 
are as follows [63]:  
 people with HIV infection,  
 people who are suffering from malnutrition, 
 people who have diabetes,  
 people who have chronic liver disease,  
 people who are suffering from renal failure, 
 patients who are at the end stage of kidney 
disease, 
 patients who are suffering certain cancers 
(head and neck cancer) and are taking 
treatment of chemotherapy,  
 some drugs users who to treat rheumatoid 
arthritis, Crohn’s disease and psoriasis,  
 infants and young children under-5, 
 people who became infected with TB 
bacteria in the last 2 years,  
 people who inject illegal drugs or drink 
alcohol,  
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 use of tobacco greatly increases the risk of 
getting TB and dying from it, 
 people who are sick with other diseases that 
weaken the immune system,  
 low body weight (10% below ideal), 
 elderly people, and  
 people who were not treated correctly for 
TB in the past.  
     TB is caused by a bacterium called 
Mycobacterium tuberculosis also called Acid-
Alcohol Fast Bacilli (AAFB) because of its staining 
properties. This rod-shaped bacterium, also called 
Koch’s Bacillus, was discovered by Dr. Robert Koch 
in 1882. Characteristics of M. tuberculosis are as 
follows [60]: 
1. It is a small, slow-growing bacterium that 
can live only in people. It is not found in 
other animals, insects, soil, or other non-
living materials.  
2. It is an aerobic bacterium, i.e., it needs 
oxygen to survive. For this reason, during 
active TB disease, M. tuberculosis 
complexes are always found in the upper air 
sacs of the lungs.  
     When M. tuberculosis bacteria enter the human 
body through breathes, causes TB infection. The 
immune system of human body cannot stop TB 
bacteria from growing and spreading after the initial 
infection. A positive TB skin test, blood test and old 
scars on a chest X-ray, may provide the evidence of 
the infection [8]. 
      TB remains a major global health problem and 
ranks as the second leading cause of death from an 
infectious disease worldwide, after the human 
immunodeficiency virus (HIV). About 2 billion 
people, one-third of the world’s population, are 
thought to be infected with TB bacterium, M. 
tuberculosis. In addition, new infections are 
occurring at the rate of one per second. TB case rates 
vary by factors such as age, race and ethnicity, and 
country of origin. In 2012, an estimated 8.6 million 
people developed TB and 1.3 million died from the 
disease. The estimated number of TB deaths among 
HIV-positive people in 2011 was 336,000 and in 
2012 was 320,000 [62].  
     The global TB mortality rate was 29 per 100,000 
in 1990 and increased to peak at 32 per 100,000 in 
2000 before decreasing to 27 per 100,000 in 2007. 
WHO has set the goal to reduce TB mortality below 
15 per 100,000 by 2015 [53]. It is expected that the 
number of TB related deaths will rise from 3 million 
per year to 5 million by 2050. TB is not only a 
problem for the health of the individuals, but also a 
major obstacle to the economic and social 
development for the developing countries [59]. 
     In 2008, TB mortality in the USA was 0.2 per 
100,000 [5]. More than 95% of TB deaths occur in 
low- and middle-income countries of the world. In 
2012, an estimated 530,000 children became ill with 
TB and 74,000 HIV-negative children died of TB. 
The TB death rate dropped 45% between 1990 and 
2012. An estimated 22 million lives saved through 
use of directly observed treatment, short-course 
(DOTS) and the Stop TB Strategy recommended by 
WHO [64]. DOTS is a five-point package; i) Strong 
Government commitment to TB control activities, 
with adequate and sustained financing, ii) ensure 
early case detection, and diagnosis through quality-
assured bacteriology, iii) provide standardized 
treatment with supervision and patient support, iv) 
ensure uninterrupted effective drug supply and 
management, and v) standardized system of patient 
records and reporting that allows supervision and 
assessment of the TB control programmes. This 
strategy was produced by Dr. Arata Kochi, who 
became the Director of the WHO TB Programme in 
1989, with the assistance of a number of TB 
specialists [39]. The first targets set by the WHO for 
the DOTS strategy is the establishment of a system 
that will cure 85% of all sputum smear positive 
patients, and second is the achievement of 70% 
detection rate [20]. 
      In Bangladesh TB control programme is 
implemented by the Government of Bangladesh 
(GoB), with various NGOs and several private and 
corporate sectors. About 40 public hospitals 
including medical college hospitals and military 
hospitals and some private hospitals have been 
involved to control TB in Bangladesh [55]. 
      Blacks continue to have an inconsistent share of 
TB and the percentage of TB cases in blacks is higher 
globally. In the 95% of all cases, 99% of death occurs 
in developing countries, with the greatest burden in 
Sub-Saharan Africa (SSA) and Southeast Asia. So 
that prevention and control efforts should be targeted 
to these population.  
      In India alone, it is estimated that about 500,500 
people died of TB in 2013 (not including those 
infected with HIV), making it the biggest killer 
among the three. India was far behind the rest of the 
world when it came to reducing prevalence of TB. 
The world prevalence of TB in those without 
HIV/AIDS in 2013 was 160.2 for every 100,000 
people but in India, it was 275.3 [41]. 
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2. Objective of the Study 
 
       The objective of the study is; to cure the patient 
and restore quality of life and productivity, to prevent 
death from active TB or its late effects, to prevent 
relapse of TB, to reduce transmission of TB to others, 
to the development and transmission of drug 
resistance TB. We want a TB free world so that it not 
only reduce sufferings of TB patients but also reduce 
economic burden of the nations. Our attempts are to 
advice about high-quality continuous care for all 
people with TB, prevention and control of TB and 
treatment of TB. We hope in our study will help the 
TB patients to take medicine properly to avoid 
multidrug-resistance TB. Our objective is to 
encourage researchers to invent drug resistant TB 
medicines, so that none will die from TB.  
 
3. History of TB 
 
      Consumption, phthisis, scrofula, Pott’s disease, 
and the White Plague are all terms used to refer to TB 
throughout history. Analysis of mycobacterial 
interspersed repetitive units has allowed dating of the 
bottleneck to approximately 40,000 years ago, which 
corresponds to the period subsequent to the 
expansion of Homo sapiens out of Africa. The term 
phthisis first appeared in Greek literature around 460 
BC. Hippocrates identified the illness as the most 
common cause of illness in his time. He stated that it 
typically affected individuals between 18 and 35 and 
was nearly always fatal. Evidence of tubercular decay 
has been found in the spines of Egyptian mummies 
thousands of years old, and TB was common both in 
ancient Greece and Imperial Rome [67].  
     Various studies have enabled scientists to 
hypothesize that M. tuberculosis evolved from the 
closely related mycobacterium, M. bovis, possibly 
coincident with the domestication of cattle by 
humans approximately 15,000–20,000 years ago [9]. 
Studies have identified TB in mummies from Egypt 
dating back 5,400 years [7, 10]. Skeletal remains 
show TB had spread throughout Europe and the 
Middle East during the Stone Age [37]. Notable 
advances in understanding the pathophysiology and 
clinical manifestations of TB occurred during the 
17th, 18th, and early 19th centuries [4]. 
     By linking the disease to its social context, 
scientists and political leaders advocated for social 
reform with mechanisms such as better nutrition, 
improved sanitation, and better housing to reduce the 
disease. Late in the 1800s, isolation and treatment of 
TB patients in Sanatoria [12] and the pasteurization 
of milk to eliminate the threat of M. bovis were 
highly visible attempts to control TB. In the 1940s, 
scientists discovered that the antibiotic, streptomycin, 
killed M. tuberculosis; however, the bacilli had a 
propensity to develop resistance to antibiotics when 
only streptomycin was used. By 1950, combined drug 
treatment was established and, a few years later, 
Isoniazid was introduced as a “miracle” cure for TB 
when combined with properly chosen drug 
combinations for sufficient duration [11]. 
     Since that time, scientific advances, including the 
discovery of the tuberculosis mycobacterium and the 
development of new drugs and the Bacille Calmette-
Guérin (BCG) vaccine, caused TB to lessen its grip 
on mankind during some periods of history. Albert 
Calmette, a French physician and bacteriologist, and 
his assistant and later colleague, Camille Guérin, 
invented BCG in 1919. The BCG vaccine was first 
used in humans in July 18, 1921 [14].  
     The vaccine was used increasingly in Europe 
during the 1920s, with early evidence for its efficacy 
coming from studies of student nurses in Norway. 
The first formal trials of BCG were organized among 
North American Indians in the 1930s [18]. By the 
late 1940s several studies had provided evidence for 
the utility of BCG in protection against tuberculosis 
[3]. Tuberculosis emerged as a major concern in the 
aftermath of World War II, and use of BCG was 
encouraged subsequently in many countries, 
stimulated in particular by UNICEF and by 
Scandinavian Red Cross Societies, and then by the 
WHO. Only two countries the USA, the Netherlands 
have never recommended to use universal BCG 
because of the low risk of infection with M. 
tuberculosis [13].  
     BCG vaccines are produced by 40 or more 
manufacturers around the world. The major 
commercial producers in terms of export volume are 
Pasteur-Merieux-Connaught, Evans-Medeva, and the 
Japan BCG Laboratory, which together accounted for 
85% of 217 million (infant, 0.05 ml) doses provided 
through UNICEF in 1996 and 1997. An estimated 
25–30% of the world’s BCG supply is purchased by 
UNICEF for distribution to developing countries 
[13]. 
     BCG vaccination should not be given to persons 
who are immunosuppressed (e.g., persons who are 
HIV infected) or who are likely to become 
immunocompromised (e.g., persons who are 
candidates for organ transplant). BCG vaccination 
should not be given during pregnancy. BCG does not 
always protect people from getting TB. Effective 
drug treatments were first developed in the 1940s. 
BCG vaccine is an injection that has been prepared 
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from a strain of the weakened live bovine 
tuberculosis bacilli. The most effective first-line anti-
TB drug, Rifamapicin, became available in the 1960s 
[59]. 
      Tuberculosis was declared a global emergency by 
the WHO in 1993, and M. tuberculosis is now 
considered to be responsible for more adult deaths 
than any other pathogen [29]. 
      At present various international organizations are 
working for the reduction of TB as follows [45]: 
1. The Stop TB Partnership (Stop TB), 
launched in 1998 and hosted by the World 
Health Organization (WHO), is a global 
network of public and private organizations, 
including TB control programmes, technical 
agencies, service delivery organizations, 
research scientists, and donors. Stop TB 
raises awareness about the global TB burden 
and coordinates the activities of partners in 
key areas, including advocacy, technical 
support, and research and development 
(R&D).  
2. The Global Drug Facility, run by the Stop 
TB Partnership, was established in 2001 to 
expand access to high-quality, affordable 
anti-TB drugs and diagnostics, and to carry 
out drug procurement for Green Light 
Committee (GLC) approved programmes.  
3. In 2000, the Green Light Committee 
Initiative was established to expand access 
to second-line anti-TB drugs for the 
treatment of strains of TB that are resistant 
to standard first-line drugs, known as 
multidrug-resistant TB (MDR TB). The 
GLC is administered by WHO.  
4. The Global Fund to Fight AIDS, TB and 
malaria is the world’s largest international 
source of financing for the global response 
to TB. It was created in 2002 as an 
innovative financing mechanism to raise and 
disburse funding to countries. As a global 
public-private partnership, the Global Fund 
uses a demand driven, performance-based 
model. Countries apply for grants to fund 
their response to TB, and continued 
financing is dependent on achievement of 
agreed upon targets. By the end of 2008, the 
Global Fund had approved $3.1 billion in 
grants to TB programmes. In 2008, the 
Global Fund contributed 57% of all 
international (non-domestic) investments for 
TB. 
 
4. Symptoms of TB 
 
        An individual may not notice any symptoms of 
illness until the disease is quite advanced. Early 
symptoms of active TB disease can include cough 
(coughing up blood) more than 2 weeks, unexplained 
weight loss, consistent low-grade fever, chills, 
haemoptysis, excessive night sweats, and loss of 
appetite [58]. Symptoms may be vague and go 
unnoticed by the affected person. The disease either 
goes into lessening or becomes chronic and more 
debilitating with cough, chest pain, bone pain if the 
bacteria have invaded the bones and bloody sputum 
(saliva). Signs and symptoms of TB of the lungs are; 
i) coughing that lasts three or more weeks, ii) 
coughing up blood or sputum (phlegm from deep 
inside the lungs), and iii) chest pain, or pain with 
breathing or coughing. When TB occurs outside the 
lungs, signs and symptoms vary according to the 
organs involved. For example, TB of the spine may 
produce back pain, and TB in kidneys might cause 
blood in urine, etc. [63]. 
      When a person’s immune system is strong, it 
builds a wall around the germs so they cannot spread 
and hurt the body. These walls are called ‘tubercles’ 
that is why the disease is named tuberculosis. TB 
bacteria can remain in this latent state for months, 
years, and even decades without increasing in 
number and without signs and symptoms, or 
radiographic or making the person sick. This is called 
latent TB infection (LTBI). People who have LTBI 
do not get sick, never show any symptoms of TB and 
do not spread the bacteria to others. Only about 10% 
of people infected with M. tuberculosis ever develop 
tuberculosis disease. Most people with LTBI will test 
positive on the tuberculin skin test (TST) or their 
chest X-ray will show signs of latent TB. Although 
most initial infections have no symptoms and people 
overcome them, they may develop fever, dry cough, 
and abnormalities that may be seen on a chest X-ray. 
This is called primary pulmonary TB and it 
frequently goes away by itself, but in 50%–60% of 
cases, the disease can return. It is important to get the 
appropriate treatment and get rid of the bacteria even 
in LTBI [6]. 
      TB pleuritis may occur in 10% of people who 
have the lung disease from TB. The pleural disease 
occurs from the rupture of a diseased area into the 
space between the lung and the lining of the 
abdominal cavity. These patients have a 
nonproductive cough, chest pain and fever. The 
disease may go away and then come back at a later 
date. In a minority of people with weakened immune 
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systems, TB bacteria may spread through their blood 
to various parts of the body. This is called miliary TB 
and produces fever, weakness, loss of appetite, and 
weight loss; cough and difficulty breathing are less 
common [58]. 
     About 15% of people may develop tuberculosis in 
an organ other than their lungs. About 25% of these 
people usually had known TB with inadequate 
treatment. The most common sites are; lymph nodes, 
genitourinary tract, bone and joint sites, meninges, 
and the lining covering the outside of the 
gastrointesrinal tract [59].   
 
5. Infection of TB 
 
      When a person breathes in M. tuberculosis 
contaminated air, the inhaled TB bacteria reach the 
lungs, which causes an infection. TB is primarily an 
airborne disease. Only people with active TB can 
spread the disease to other. The bacteria are spread 
from person to person through tiny microscopic 
droplet nuclei (1–5 μm in diameter, invisible to the 
naked eye) when a TB sufferer coughs, spits, sneezes, 
speaks, shout, sings, or laughs and another person 
inhales the infected air. TB germs can float in the air 
for several hours, so it is possible to inhale them even 
when the sick person is left the room [8]. The active 
bacteria multiply and destroy the tissues of the 
infected person. A person with TB disease shows 
symptoms that vary, depending on where the TB 
bacteria are growing and in most cases, the bacteria 
attack the lungs. TB is not spread by shaking 
individual’s hand, sharing food or drink, touching 
bed linens or toilet seats, kissing and sharing 
toothbrushes. To avoid TB an individual have to 
avoid long periods of time in enclosed rooms with 
someone who has TB, air out those rooms regularly 
and need a cover face with a mask [56].  
    To control TB infection we need the following 
three steps: 
 prompt detection of infectious patients,  
 airborne precautions, and  
 treatment of people who have suspected or 
confirmed TB disease. 
 
5.1 Infection Control Policy 
 
     Infection of TB control is a combination of 
measures aimed at minimizing the risk of TB 
transmission within people. For this we need the core 
interventions in TB control, HIV control and 
strengthening of health systems. For the successful 
implementation of TB infection control needs the 
followings [56]. 
 sound technical guidance, 
 coordination between health authorities at 
national and sub-national level, 
 adequate funding at all levels, 
 coordinated efforts from ministries of health, 
finance, justice, labor, public works and 
environment, 
 coordination between different national 
disease-specific programmes, 
 contributions from technical partners and 
civil society, and 
 major advocacy mobilization to remove 
obstacles that impede wide implementation 
of activities. 
 
6. Classification of TB Cases 
 
     Cases of TB are classified according to the 
following rules [58]: 
 anatomical site of disease, 
 bacteriological results (including drug 
resistance), 
 history of previous treatment, and 
 HIV status of the patient. 
     A bacteriologically confirmed TB case is one 
from whom a biological specimen is positive by 
smear microscopy, culture or WHO-approved rapid 
diagnostics (WRD), such as Xpert MTB/RIF. A 
clinically diagnosed TB case is one who does not 
fulfill the criteria for bacteriological confirmation but 
has been diagnosed with active TB by a clinician or 
other medical practitioner who has decided to give 
the patient a full course of TB treatment [63].  
     Pulmonary TB (PTB) refers to a case of TB 
involving the lung parenchyma. Miliary TB is 
classified as pulmonary TB because there are lesions 
in the lungs. Extrapulmonary TB (EPTB) refers to a 
case of TB involving organs other than the lungs (i.e., 
without radiographic abnormalities in the lungs), e.g. 
pleura, lymph nodes, abdomen, genitourinary tract, 
skin, joints and bones, meninges. A patient with both 
pulmonary and extrapulmonary TB should be 
classified as a case of pulmonary TB [27]. 
       New TB patients are those who never have taken 
any treatment of TB. Previously treated patients are 
those who have received 1 month or more of anti-TB 
drugs in the past. Treatment after failure patients are 
those who have previously been treated for TB and 
whose treatment failed at the end of their most recent 
course of treatment. HIV-positive TB patient refers to 
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any bacteriologically confirmed or clinically 
diagnosed case of TB who has a positive result from 
HIV testing conducted at the time of TB diagnosis or 
other documented evidence of enrolment in HIV 
care, such as enrolment in the pre-antiretroviral 
therapy (ART) register or in the ART register once 
ART has been started [63]. 
 
7. Higher TB Risk Regions and 
Communities in the World 
 
    High incidence areas are defined as areas with 
reported or estimated incidence of ≥ 20 cases of TB 
per 100,000 populations. High prevalence areas are 
defined as areas with reported or estimated 
prevalence of ≥ 20 cases of TB per 100,000 
populations. TB mostly affects young adults, in their 
most productive years [8].  
    Health care providers are in high risk of TB 
infection, as they always come into the contact of TB 
infected people. People who live or work in prisons, 
immigration centers are all at the risk of TB due to 
overcrowding and poor ventilation (adequately 
ventilated room has at least 12 air changes per hour). 
People who live in refugee camp or shelter are in the 
high risk of infection of TB due to poor nutrition and 
ill health, and living in crowded, unsanitary 
conditions. Army barracks of some countries are in 
congregate settings and are in the risk of TB infection 
[21].  
 
7.1 Higher TB Risk Regions 
 
     More than 95% of cases and deaths due to TB are 
in developing countries. Higher rates of TB are in the 
following regions [66]:  
 Sub-Saharan Africa (Ethiopia, Kenya, 
Nigeria, Mozambique, South Africa, 
Uganda, The Democratic Republic of 
Congo, The United Republic of Tanzania 
and Zimbabwe),  
 India, Bangladesh, Pakistan, Myanmar, 
Afghanistan, 
 China, Cambodia, Vietnam,   
 Mexico,  
 most countries in Latin America and the 
Caribbean, 
 Eastern Europe, 
 the islands of Southeast Asia and Micronesia 
(The Philippines, Indonesia), and  
 parts of the former Soviet Union.  
     India alone accounts for an estimated one-quarter 
(26%) of all TB cases worldwide and only China and 
India combine accounting for 38% [60]. In BRICS 
(Brazil, the Russian Federation, India, China and 
South Africa) that have almost 50% of global TB 
cases. In 2012 the highest levels of MDR TB are 
found in Eastern Europe and central Asia, where in 
some countries more than 20% of new TB cases and 
more than 50% of those previously treated for TB 
have MDR TB [62]. Bangladesh is in rank 6th among 
the countries with a high TB burden and ranks 5th 
among 22 countries with global burden of TB [50]. 
Thailand is ranked 18th of the top 22 highest TB 
burdened countries [28]. High TB prevalence areas 
are more in the low- to middle-income countries, due 
to lack of effective control programmes [21]. 
 
7.2 TB Risk among Health Care 
providers 
 
      Health care providers (doctors, nurses, 
pharmacists and laboratory technicians, health 
management and workers in health care centers) in 
the TB cure centers always come into the contact of 
TB infected people. When patients with TB visit for 
health care facilities, they are likely to transmit the 
disease to the health care providers (HCPs) and are in 
the higher risk of infection of TB. The infected HCPs 
also spread TB bacteria to the healthy people. The 
patients with multidrug-resistant TB (MDR TB) and 
extensively drug-resistant TB (XDR TB) have 
relatively higher morbidity, which are difficult or 
sometimes impossible to treat successfully and visit 
the HCPs more frequently. HCPs often work in 
potentially incurable TB wards, where palliative and 
end-of-life care are being considered. The prevalence 
of latent TB infection (LTBI) in nurses has been 
found to be 1.3% to 35.6% times higher than other 
HCPs [15, 17, 68]. They must wear masks and 
frequent hand washing can reduce the risk of 
infecting TB. 
      Health care facilities in low- and medium-income 
countries had a median of 36 HCPs per 100 TB 
patients treated at the facility, which is much lower 
than facilities in high-income countries, which have a 
median of 6,450 HCPs per 100 TB patients [22]. 
Nosocomial transmission of TB in India is 5% per 
year to the HCP in comparison to the national 
average of 1.5% [27]. Nosocomial infection is an 
infection occurring in a patient in a hospital or other 
health-care centers in whom the infection was not 
present or incubating at the time of admission. This 
includes infections acquired in the hospital but 
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appearing after discharge, and also occupational 
infections acquired by staff as a result of working at 
the facility [56]. 
      The risk as compared with general population is 
highest among workers in TB in-patient facilities, 
laboratories (sputum collection areas and 
bronchoscopy rooms), general medicine wards, and 
emergency rooms. Workers in out-patient medical 
facilities have an intermediate risk, while workers in 
surgery, obstetrics, administration and operating 
theaters have the lowest risk [26]. 
  
7.3 TB Risk in Prisons 
 
     About 10 million people are detained worldwide 
(1.5 million in China and 0.89 million in Russia) in 
jails, prisons, detention centers and risk of TB 
remains a growing problem among them. The poor 
living conditions for prisoners are in India, 
Bangladesh, Sri Lanka, Afghanistan, Thailand, Brazil 
and SSA. The prisons of the developing countries 
keep two to five times more prisoners than they were 
meant to [19]. 
      Prisoners are overwhelmingly male, are typically 
aged 15–45 years, and come mainly from poorly 
educated and socioeconomically deprived sectors of 
the population where TB infection and transmission 
are higher. Majority portion of them are involve with 
drug addiction and alcohol. A minor portion of them 
suffer from liver disease. As a result risk of TB 
infection remains a growing problem in jails, prisons, 
detention centers. TB incidence is 5 to 70 times 
greater in prisons than in general people, because of 
severe overcrowding, poor nutrition, poor ventilation 
and limited access to often insufficient health care 
[47, 51]. 
     The International Red Cross reports that the rate 
of TB infection in Kyrgyzstan prisons was 40 times 
that in the civilian population while in Peru, the TB 
infection rate in prison was 49 times that outside 
prison. Some countries in SSA TB infection rates per 
100,000 in prisons are 3,797 in Botswana, 1,100 in 
Malawi and in Zambia 4,000 [38]. 
      TB cases in prisons are not just about prisoners. 
TB in prisons threatens inmates and prison staffs, 
custodial staffs and health staffs, as they are entering 
and leaving every day. They are at particular risk of 
infection of TB. Visitors to prisons may also have 
regular close contact with the prisoners. Sooner or 
later, prisoners are released and mix with people of 
different levels. Any health problem among the 
prisoner population will inevitably affect those 
people in close contact with them, and ultimately 
these problems will spill out into the innocent 
common people. Effective tuberculosis control in 
prisons is necessary to protect the wellbeing of both 
prisoners and the wider community. Prisons in SSA 
have no proper facilities to treat MDR TB and XDR 
TB. Some countries of SSA do not express the data 
of drug-resistant TB in prisons [32, 51]. 
 
8. TB and HIV Co-infection 
 
      HIV infection is the major cause to the increase 
of TB across the world. About 9% of adults globally 
with newly diagnosed TB are HIV positive, but this 
rate is 31% in Africa. HIV co-infection with TB 
presents challenges to effective diagnosis of TB and 
diagnosis can also be more difficult in children [16]. 
     High levels of HIV patients are seen in prisons 
which is a great problem on prison-seated TB 
epidemics. In several countries the numbers of TB 
patients become 4 times in the last 2 decade as a 
result of HIV. In some countries about 75% of TB 
patients are HIV-positive. TB is the single biggest 
killer of people infected with HIV [62]. 
     The risk of progression from LTBI to TB disease 
is 7% to 10% each year for those with both LTBI and 
untreated HIV infection. People who are co-infected 
with HIV and TB are 21 to 34 times more likely to 
become sick with TB. This risk is reduced with ART 
for HIV. About half a million children (0–14 years) 
fell ill with TB, and 74,000 HIV-negative children 
died from the disease in 2012. In 2012 about 320,000 
people died of HIV-associated TB. At least one-third 
of people living with HIV worldwide in 2012 are 
infected with TB bacteria, although not yet ill with 
active TB. In 2012 there were an estimated 1.1 
million of HIV-positive new TB cases, 75% of whom 
were living in Africa. The TB epidemic in SSA is 
increased due to HIV epidemic, and up to 70% of 
adults with TB are co-infected with HIV [6]. 
 
9. Diagnosis for TB 
 
       There are two kinds of tests that are used to 
determine if a person has been infected with TB 
bacteria; (i) the tuberculin skin test (also called the 
Mantoux tuberculin skin test since 1910) and (ii) TB 
blood tests. The tuberculin skin test (TST) is the 
oldest test for TB and is especially useful in testing 
children. This test is easy, less expensive and less 
biological variability in serial testing, but operator 
dependence is difficult. It is often used for initial 
screening in developed counties, although it is under-
utilized in Africa and Asia. To identify those who 
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may have been exposed to M. tuberculosis, doctors 
typically inject a substance called tuberculin (0.1ml 
of 5 TU purified protein derivative (PPD) solution) 
under the skin (volar surface) of the forearm using a 
27-gauge needle with a tuberculin syringe, which is 
called skin test. TST is both safe and reliable 
throughout the course of pregnancy [6]. If a red welt 
forms around the injection site within 72 hours, the 
person may have been infected. The size of the bump 
(measure its size using a ruler) determines whether 
the test results are significant [31].  
     But TST does not necessarily mean one has active 
TB disease. The QuantiFeron-TB Gold test is a blood 
test that can detect infection and latent TB, and 
results are available in as little as 24 hours and 
measure how the immune system reacts to the 
bacteria that cause TB. This blood test is very useful 
because it is not subject to reader bias, and BCG 
immunization does not affect the results [30].  
    The most common method for diagnosing TB 
worldwide is sputum smear microscopy (first 
developed in the 1880s and basically unchanged 
today), in which bacteria are observed in sputum 
samples examined under a microscope. Sputum 
examination is indicated for persons with positive test 
results for TB infection and either an abnormal chest 
radiograph or the presence of respiratory symptoms 
[6, 62]. Only an estimated 45% of infections are 
detected and the smear-negative diseases cannot be 
detected by sputum microscopy. It has the advantage 
of being simple, but is hampered by very low 
sensitivity. It is also very dependent on the skill of 
the technician, and a single technician can only 
process a relatively small number of slides per day 
[33]. A newly developed diagnostic test is the 
Interferon-Gamma Release Assay (IGRA) which is a 
T-cell based assay. This blood test is complicated and 
high expensive, but can be more specific than TST 
for diagnosing latent TB. IGRAs are also required a 
high level of experience to manage [35]. 
     An IGRA measures how strong a person’s 
immune system reacts to TB bacteria by testing the 
person’s blood in a laboratory. IGRAs, unlike the 
TST, are not affected by prior BCG vaccination and 
are not expected to give a false-positive result in 
people who have received BCG. Two IGRAs that 
have been approved by the US Food and Drug 
Administration (FDA) are commercially available in 
the USA; i) QuantiFERON®-TB Gold In-Tube test 
(QFT-GIT) and ii) T-SPOT®.TB test (T-Spot). The 
interpretation of IGRAs is based on the amount of 
INF-γ released, in QFT, or on the number of cells that 
release INF-γ, in T-SPOT®.TB. IGRAs are the 
preferred method of testing for groups of people who 
have poor rates of return for TST reading and 
interpretation and persons who have received BCG 
vaccination [6]. 
      A positive TB skin test or TB blood test only tells 
that a person has been infected with TB bacteria. It 
does not tell whether the person has LTBI or already 
infected with TB. Other tests, such as a chest X-ray 
and a sample of sputum are needed to see whether the 
person has TB disease. A negative test means that the 
person’s blood did not react to the test and that latent 
TB infection or TB disease is not likely. People who 
had a severe reaction to a previous TST should not 
receive another TST. In general, a person should 
have either a TST or an IGRA, but not both. Chest X-
ray helps differentiate between LTBI and pulmonary 
TB disease in patients with positive tests for TB 
infection. Children under-5 should have both 
posterioranterior and lateral views; all others should 
have at least posterioranterior views [6]. 
     People who may test positive on the tuberculin 
test are as follows: 
 people with previous experience to M. 
tuberculosis,  
 people who have not taken TB vaccine 
before, and 
 one was vaccinated with the TB vaccine but 
it was not given in full dose or it may be in 
expire dated.  
     A positive TB skin test, and white spots on a chest 
X-ray in lungs where immune system has walled off 
TB bacteria, may provide the only evidence of the 
infection. Blood tests may be used to confirm or rule 
out latent or active TB. 
     The doctors also will take sputum and other 
samples to see if the TB bacteria will grow in the 
laboratory. If bacteria are growing, this positive 
culture confirms the diagnosis of TB. Because M. 
tuberculosis grows very slowly, it can take 4 weeks 
to confirm the diagnosis. An additional 2 to 3 weeks 
usually are needed to determine which antibiotics to 
use to treat the disease. TB is particularly difficult to 
diagnose in children. The gold standard for TB 
testing is chest radiography, which will reveal 
lesions, cavities, scar tissue, and calcium deposits 
[25]. Physical examination and medical history, 
which includes finding information about previous 
positive tests for TB infection, previous treatment for 
LTBI or TB disease, and a risk assessment for liver 
disease, are indicated for an individual with positive 
TB test results. Written documentation of a 
previously positive TST or IGRA result is required; a 
patient’s verbal history is not sufficient [6]. 
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10. Treatment for TB 
 
     TB bacteria become active if the immune system 
cannot stop them from growing. When TB bacteria 
are active, this is called TB disease. Applying 
appropriate antibiotic treatment, TB can be cured in 
most patients. Successful treatment of TB depends on 
close cooperation between patients and healthcare 
providers. For latent TB, patient may need to take 
just one TB drug but for TB disease, doctor will 
prescribe several medicines of duration for 6 months 
or longer. 
 
10.1 Treatment of LTB Patients 
 
    There are two options for treatment with Isoniazid 
(INH): i) 9-month regimen, and ii) 6-month regimen. 
The 9-month regimen is preferred because it is more 
efficacious. The preferred regimen for children aged 
2–11 years is 9 months of daily INH. The directly 
observed 12-dose once-weekly regimen of INH and 
Rifapentine (RPT) is recommended as an option 
equal to the standard INH 9-month daily regimen for 
treating LTBI [6].  
    The 12-dose regimen can be considered for healthy 
HIV-infected persons, 12 years of age and older, who 
are not on ART medications. It may also be 
considered for children aged 2–11 years if 
completion of 9 months of INH is unlikely and 
hazard of TB disease is great. The 12-dose regimen is 
not recommended for children younger than 2 years 
of age, people with HIV/AIDS who are taking ART, 
people presumed to be infected with INH or 
Rifampin-resistant M. tuberculosis, pregnant women, 
or women expecting to become pregnant while taking 
this regimen. A 4-month regimen of Rifampin (RIF) 
can be considered for persons who cannot tolerate 
INH or who have been exposed to INH-resistant TB. 
It should not be used to treat HIV-infected persons 
taking some combinations of ART [6]. 
 
Drug Daily 3 times per week 
Dose and range (mg/kg 
body weight) 
Maximum 
(mg) 
Dose and range (mg/kg 
body weight) 
Daily 
maximum 
(mg) 
Isoniazid 5 (4–6) 300 10 (8–12) 900 
Rifampicin 10 (8–12) 600 10 (8–12) 600 
Pyrazinamide 25 (20–30) – 35 (30–40) – 
Ethambutol 15 (15–20) – 30 (25–35) – 
Streptomycin 15 (12–18) – 15 (12–18) 1,000 
 
Table 1: Recommended doses of first-line anti-tuberculosis drugs. Source: [52]. 
 
10.2 Treatment of Active TB Patients 
 
     To make easy procurement, allocation and 
management of treatment to patients, the daily 
dosage may be standardized for three or four body 
weight bands, such as, 30–39 kg, 40–54 kg, 55–70 kg 
and over 70 kg [34]. Table 1 shows the essential anti-
TB drugs and their recommended dosages based on 
the patient’s weight. 
     Patients aged over 60 years may not be able to 
tolerate Streptomycin more than 500–750 mg daily, 
so some guidelines recommend reduction of the dose 
to 10 mg/kg per day in patients in this age group. 
Patients weighing less than 50 kg may not tolerate 
doses above 500–750 mg daily [2]. 
     Schedules for treating TB disease have an initial 
phase of 2 months, followed by a choice of several 
options for the continuation phase of either 4 or 7 
months (total of 6 to 9 months for treatment) and 
sometimes longer (1 or 2 years) and can be cured in 
almost all cases by taking the medications as 
prescribed by the doctor for the full course of 
treatment. The exact drugs and length of treatment 
depend on age, overall health, possible drug 
resistance, the form of TB (latent or active) and the 
infection’s location in the body. Recently a shorter 
term of treatment, 3 months instead of 9, with 
combined medication may be effective in keeping 
latent TB from becoming active TB. With the shorter 
course of treatment, patients are more likely to take 
all their medication and the risk of side-effects is also 
lessened. For latent TB the patients need to take just 
one type of TB drug. But in active TB, particularly if 
it is a drug-resistant strain, will require several drugs 
at once. The most common medications (the first-line 
anti-TB agents) used to treat TB are Isoniazid (INH), 
Rifampin (RIF), Ethambutol (EMB) and 
Pyrazinamide (PZA). In addition, doctor may 
 American Journal of Infectious Diseases and Microbiology, 2015, Vol. 3, No. 1, 18-31 
 
10 
 
recommend vitamin B6 (Pyridoxine) to prevent 
specific side-effects of INH [58].  
     Without treatment, a person with TB disease can 
progress from sickness to death. In studies of the 
natural history of the disease among sputum smear 
positive/HIV-negative cases of pulmonary TB, 
around 70% died within 10 years; among culture-
positive (but smear negative) cases, 20% died within 
10 years [42]. 
 
10.3 Patient Group Treatment 
 
    Patient group treatment is called standardized 
treatment which means that all patients in a defined 
group receive the same treatment regimen. 
Advantages of this type of treatment are as follows: 
 the risk of development of drug resistance 
are reduced by avoiding prescription errors, 
 costs are reduced, 
 maintaining a regular drug supply when 
patients move from one area to another is 
made easier, 
 outcome evaluation is convenient and results 
are comparable, and 
 estimating drug needs, purchasing, 
distribution and monitoring are facilitated.   
 
11. Side-effects of TB Medicines 
 
     Like all medicines, the medicines are taken to cure 
TB infection can have side-effects. However, most 
people can take their TB medicines without any 
problems. The side-effects of TB medicines are as 
follows [1]:  
1. Dizzy or lightheaded when sitting, standing 
or lying down.  
2. Less appetite or no appetite for food.  
3. Stomach upset, nausea, or vomiting.  
4. Flu-like symptoms with or without fever.  
5. Severe tiredness.  
6. Aches in joints   
7. Fevers or chills. 
8. Pain in lower chest or heartburn.  
9. Severe diarrhea or light colored stools. 
10. Shortness of breath. 
11. Brown, tea-colored, or cola-colored urine.  
12. Skin or whites of eyes appear yellow.  
13. Skin rash or itching.  
14. Bruises or red and purple spots on skin that 
cannot explain.  
15. Nosebleeds or bleeding from gums or 
around teeth.  
16. Pain or tingling in hands, arms and legs.  
     Numbness or a tingling or burning sensation of the 
hands or feet and occur more commonly in pregnant 
women and in people with HIV infection, alcohol 
dependency, malnutrition, diabetes, chronic liver 
disease, renal failure. These patients should receive 
preventive treatment with Pyridoxine, 10 mg/day 
along with their anti-TB drugs. Other guidelines 
recommend 25 mg/day depending on the side-effects 
and other morbidities [23]. 
 
12. Prevention of TB 
 
TB is an airborne disease and transmission essentially 
can be prevented through adequate ventilation and 
limited contact with patients. Many people who are 
infected latent TB, healthcare providers try to 
identify people infected with this disease as early as 
possible, before they advance from latent to active 
TB. 
 
12.1 TB Prevention by BCG 
 
     At present each year about 100 million children 
receive BCG vaccine worldwide. To prevent TB, the 
WHO recommends that infants receive a BCG 
vaccine where TB is a common disease. BCG is 
fairly effective in protecting small children from 
severe TB complications, but it does not protect 
adults very well against lung TB. BCG is used in 
many countries with a high prevalence of TB to 
prevent childhood tuberculous meningitis and miliary 
disease. BCG is not generally recommended for use 
in the USA and Netherlands because of the low risk 
of infection M. tuberculosis.  BCG vaccination of 
health care workers should be considered on an 
individual basis in settings in which a high 
percentage of TB patients are infected with M. 
tuberculosis strains resistant to both Isoniazid and 
Rifampin. 
     BCG vaccination should not be given to persons 
who are immunosuppressed (e.g., persons who are 
HIV infected) or who are likely to become 
immunocompromised (e.g., persons who are 
candidates for organ transplant). BCG vaccination 
should not be given during pregnancy. 
    Priming TB vaccines (pre-exposure TB vaccines) 
is intended for use in newborns or young infants at 
the time when the individual is not yet infected with 
TB. Booster TB vaccines (post-exposure TB 
vaccines) can be given together with other childhood 
vaccines during the first year of life and also, at 
almost any time point, to school children, 
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adolescents, or adults, when the individual has either 
been vaccinated. Therapeutic TB vaccines are to be 
given to individuals with active TB disease, represent 
a special case of the above-mentioned post-exposure 
vaccines. These vaccines are used not as stand-alone 
agents, but rather as adjunct to antibiotic treatment, 
with the aim of shortening the duration of anti-TB 
chemotherapy [14]. 
     A number of BCG vaccine strains are available, 
although the French Pasteur strain 1173 P2, the 
Danish strain 1331, the Glaxo strain 1077 and the 
Tokyo strain 172 account for about 90% of BCG 
vaccinations worldwide. 
 
12.2 Environmental Controls to Prevent 
TB 
 
      Environmental controls of TB indicate the use of 
engineering technologies to help prevent the spread 
and reduce the concentration of infectious droplet 
nuclei in the air. The existing ventilation system in a 
medical hospital or a clinic may not have sufficient 
safeguards to prevent the spread of TB or some of the 
hospitals and clinics have no ventilation system at all. 
But TB clinics must need sufficient ventilation 
system and directional airflow to prevent the spread 
of TB. Ventilation is the movement of air in a 
building and replacement of inside air with air from 
the outside. In the TB clinics need two types of 
ventilations [8]: i) natural ventilation, which relies on 
open doors and windows to bring in air from the 
outside. Fans may also assist in this process and 
distribute the air and ii) mechanical ventilation, 
which usually refers to the use of mechanical air-
moving equipment that circulates air in a building 
and may also involve heating and/or cooling. 
    When clean or fresh air enters in a room, by either 
natural or mechanical ventilation, it dilutes the 
concentration of airborne droplet nuclei in room air. 
Doors, windows and skylights of the clinic must keep 
open for the movements of air to inactivate droplet 
nuclei containing M. tuberculosis. Propeller fans can 
be an inexpensive way to increase the effectiveness 
of natural ventilation. Ceiling fans, desk fans, 
standing fans and window fans can be used to 
improve ventilation in a building (TB clinic, 
dormitory, prison, refugee camp and army barrack). 
Fans help to mix air in a room to dilute any infectious 
particles by spreading them throughout the room and 
leaving outside. But this system may not possible in 
extremely cold climates [46].  
    Central ventilation systems (forced-air systems) 
are mechanical systems that circulate air in a 
building. Some buildings have a mechanical system 
with 100% recirculation where air is supplied to a 
room to provide ventilation and/or heating or air 
conditioning. This air mixes with room air and then 
returned to the unit, where it is filtered and/or heated 
or cooled before being sent back to the room. 
     Filters are used to clean air by removing particles 
from air that is passed through them. The cleaned air 
is then distributed. By filtration many particles 
containing M. tuberculosis are removed and the risk 
of spreading TB by recirculation is reduced. 
Comparing the efficiency there are three different 
types of filters: i) high-efficiency particulate air 
(HEPA) filter which remove all particles in the size 
range of TB bacteria droplet nuclei, ii) pleated 
ASHRAE 25% efficient filter (MERV 7 or 8), which 
can remove approximately half of all particles in the 
size range of TB droplet nuclei, and iii) lint filter, 
which cannot remove particles in the size range of 
TB droplet nuclei. 
     Ultraviolet germicidal irradiation (UVGI) uses a 
type of radiation that has been shown to kill or 
inactivate M. tuberculosis in air. UVGI can have 
negative short-term health effects on the skin and 
eyes, a safety plan should be implemented when it is 
used. UVGI has two applications: induct UVGI and 
upper-air UVGI. Induct UVGI the installation of UV 
lamps in a return or exhaust air duct to kill any M. 
tuberculosis. In upper-air UVGI lamps are mounted 
high on walls or suspended from the ceiling and 
radiation is directed into the upper portion of the 
room, where the air is disinfected. 
 
13. Drug Resistant (DR) TB 
 
DR TB is a rising global problem which is more 
difficult and expensive to treat and cure. DR TB can 
occur when the drugs used to treat TB are misused or 
mismanaged. People who do not take all the required 
medicines, if healthcare providers prescribe the 
wrong treatment, the wrong dose, or wrong length of 
time for taking the drugs, the supply of drugs is not 
always available; the drugs are of poor quality can 
become sick again and spread TB to others. If some 
other persons have not taken all the prescribed 
medicines or skip times when they are supposed to 
take them, the TB bacteria evolve to outwit the TB 
antibiotics. Soon those medicines no longer work 
against the disease. In this situation it is called DR 
TB. It is divided into two types: primary resistance 
and secondary resistance. Primary resistance occurs 
when a person gets infected with TB that is already 
resistant and never treated for TB before. Secondary 
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resistance occurs during treatment for TB, because 
the doctor prescribes inadequate treatment, patients 
with TB stop their treatment prematurely, or take 
their medicine at irregular intervals [8]. Rapid and 
reliable techniques for drug-susceptibility testing 
(DST) are needed urgently to save the life of the 
patient. DR TB threatens global TB control and is a 
major public health concern in several countries.  
 
13.1 Multidrug-Resistant TB (MDR TB) 
 
     MDR TB is a man-made problem created by 
health care providers and patients, in situations where 
some Rifampicin (RIF) and Isoniazid (INH) (first-
line drugs) treatment can be obtained and used 
erratically or incorrectly. Monoresistance TB is the 
resistance to one first-line anti-TB drug only. 
Polydrug resistance TB is resistance to more than one 
first-line anti-TB drug (other than both Isoniazid and 
Rifampicin). MDR TB is the resistant to at least two 
of the best Food and Drug Administration-approved 
anti-TB drugs, Isoniazid (INH) and Rifampicin 
(RIF). These antibiotics are considered first-line 
drugs and are the first medicines used to treat all 
persons with TB disease. For patients with MDR TB, 
second-line drug treatment is mandatory up to 2 
years, requiring DST of these antibiotics as well. The 
extensive chemotherapy is required to treat MDR TB 
which is more costly and can produce severe adverse 
drug reactions in patients. It is very important to 
prevent the further development of MDR TB by the 
widespread application of DOTS and other measures 
such as health education, strengthened case-finding 
and respiratory isolation of infectious drug-resistant 
cases. At the global level, 15% of previously treated 
patients have MDR, which is 5 times higher than the 
global average of 3% in new patients [52]. The WHO 
estimates that 5% of all TB cases worldwide are 
MDR TB strain. There were an estimated 0.5 million 
cases of MDR TB in 2007 and about 511,000 new 
MDR TB cases were reported. Three countries of the 
world; China, India, and Russia are accounting for 
56% of all global MDR TB cases. In 2007 only 3,681 
people (1% of the estimated global total of MDR TB 
cases) were put on treatment in projects approved by 
the GLC. More than 110,000 patients die each year 
due to MDR TB [45, 53]. There are 27 countries (15 
in the European Region) that account for 85% of all 
such cases; these countries have been termed the 27 
high MDRTB burden countries [57]. In 2010, the 
WHO estimated that more than 650,000 people have 
MDR TB. The Global Plan to Stop TB outlines scale 
up of services within TB programmes to detect and 
treat 1.6 million MDR TB cases by 2015. 
      Treatment for drug-resistant TB often requires the 
use of special TB drugs, all of which can produce 
serious side-effects. People with MDR TB may have 
to take several antibiotics, at least three to which the 
bacteria still respond, every day for up to 2 years. 
Even with this treatment 4 to 6 out of 10 patients with 
MDR TB will die. According to the WHO, there is 
slow progress in tackling MDR TB, 3 out of 4 MDR 
TB cases still remain without a diagnosis, and around 
16,000 MDR TB cases reported to the WHO in 2012 
were not put on treatment [61]. 
     The countries that ranked 1st to 5th in terms of total 
numbers of MDR TB cases in 2007 were India 
(131,000), China (112,000), the Russian Federation 
(43,000), South Africa (16,000) and Bangladesh 
(15,000) [57]. 
 
13.2 Extensively drug-resistant TB (XDR 
TB) 
 
    XDR TB is a relatively rare type of TB that is 
resistant to MDR TB (Isoniazid and Rifampin 
(Rifadin, Rimactane)), plus any Fluoroquinolone and 
at least one of three injectable second-line drugs, 
such as, Amikacin, Kanamycin, or Capreomycin. 
XDR TB cases have been detected in at least 55 
countries of the world. About 424,000 MDR TB 
cases are added each year and about 25,000 of these 
cases are expected to have XDR TB. It is estimated 
that about 9.6% of MDR TB cases had XDR TB [49, 
54]. In many developing countries, this type of TB is 
untreatable. XDR TB cases in South Africa were 
untreatable by any available drugs, and had a 
devastating mortality rate for example, 52 of 53 
patients died [65]. WHO estimated that 40,000 cases 
of XDR TB occur each year [53]. By November 
2009, 57 countries and territories had reported at least 
one case of XDR TB [57]. 
     People may get XDR TB in the following two 
ways [54]:  
1. Directly, if they spend time with an XDR 
TB patient and breathe in the XDR TB 
bacteria.  
2. If they already have MDR TB or active TB, 
and do not properly follow their prescribed 
treatment regimen or TB medication is not 
reliably available to them.  
    XDR TB is resistant to first-line and second-line 
drugs, patients are left with limited treatment options 
that are much less effective. XDR TB is of special 
concern for people with HIV infection and has a 
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higher risk of death once they develop TB. Although 
MDR and XDR TB are occurring globally, they are 
still rare. In 2011, almost 2 out of every 100 TB cases 
were resistant to at least two antibiotics [60].   
    Rifampicin-resistance TB (RR TB) is resistance to 
Rifampicin detected using phenotypic or genotypic 
methods, with or without resistance to other anti-TB 
drugs. It includes any resistance to Rifampicin, 
whether monoresistance, MDR, polydrug resistance 
or XDR [63].   
 
14. Drug Susceptibility Testing 
 
     The demand for reliable drug susceptibility testing 
(DST) increased globally due to the expansion of 
anti-tuberculosis drug-resistance surveillance, and 
with the need for an appropriate treatment of MDR 
TB. In many countries, the wide use of the standard 
short-course regimen has led to an increasing 
incidence of MDR TB, defined as resistance to at 
least Isoniazid (INH) and Rifampicin (RIF) [24, 48]. 
      It is a difficult procedure to standardize, and 
proficiency in performing the tests requires an 
understanding of many elements as follows [54]: 
1. Origin of drug resistance and the criteria for 
resistance. 
2. Potency and stability of drugs during 
laboratory manipulation.  
3. Anti-mycobacterial activity of drugs when 
incorporated into different media.  
4. Reading, interpretation, and reporting of 
results. 
     External quality assurance for DST of first-line 
drugs were begun internationally in 1993 through the 
Supranational Laboratory Network. In 2001, the 
guidance on DST for second-line drugs was 
published by WHO. Very few national TB 
programmes have capacity for DST for the first-line 
drugs and even fewer have the capacity to test for 
second-line drug resistance [49]. 
    For many years conventional DST on solid egg-
based Löwenstein-Jensen or agar-based 7H10 or 
7H11 Middlebrook media was a standard technology 
and is still utilized in many countries worldwide. 
Measurement of recent laboratory capacity indicates 
that less than 5% of MDR TB cases are currently 
detected [36]. The WHO Stop TB Department has 
three main objectives as follows: 
 to develop an interim policy document,  
 update existing technical guidelines, and  
 develop plans for external quality assurance 
of second-line DST.  
     TB bacteria M. tuberculosis complex are tested by 
this method with the drugs included; Isoniazid, 
Rifampin, Ethambutol, Ciprofloxacin, Ofloxacin, 
Streptomycin, Kanamycin, Capreomycin, Amikacin, 
Rifabutin, Ethionamide and Para-aminosalicylic acid 
(PAS). Well performing DOTS programmes reduce 
the occurrence of DR TB to a minimal level and poor 
DOTS programmes performance generates DR TB 
cases.  
 
15. Data and Statistics 
 
       TB is one of the world’s deadliest diseases after 
HIV. One-third of the world’s population is infected 
with TB and is a leading killer of people who are 
HIV infected. The majority of cases worldwide in 
2012 were in Asia (55%), in the Southeast Asia 
(29%), African (27%) and Western Pacific regions 
(19%), in the Eastern Mediterranean Region (7%), 
the European Region (5%) and the Region of the 
Americas (3%). India and China alone accounted for 
26% and 12% of total cases, respectively. In 2012, 
about 9 million people (about 3 million were women) 
around the world became sick with TB disease, 
among them 1.1 million (13%) were HIV-positive 
and about 75% of these cases were in the African 
Region. There were around 1.3 million TB-related 
deaths worldwide and about 410,000 TB deaths 
among women in 2012, including 160,000 among 
HIV-positive women. There were about 530,000 TB 
cases among children under 15 and 74,000 TB deaths 
were in 2012. Globally in 2012, an estimated 450,000 
people developed MDR TB and there were an 
estimated 170,000 deaths from MDR TB [62]. 
      A total of 9,945 TB cases (a rate of 3.2 cases per 
100,000 persons) were reported in the USA in 2012. 
Both the number of TB cases reported and the case 
rate decreased; this represents a 5.4% and 6.1% 
decline, respectively, compared to 2011 [6].  
      The five countries that rank first to fifth in terms 
of total numbers of incident cases in 2008 are India 
(1.6–2.4 million), China (1.0–1.6 million), South 
Africa (0.38–0.57 million), Nigeria (0.37–0.55 
million) and Indonesia (0.34–0.52 million). India and 
China alone account for an estimated 35% of TB 
cases worldwide. Of the 9.4 million incident cases in 
2008, an estimated 1.2–1.6 million (13–16%) were 
HIV-positive. Of these HIV-positive cases, 78% were 
in the African Region and 13% were in the South-
East Asia Region. The 22 high-burden countries are 
shown in table 2 which account for 80% of all 
estimated cases worldwide [57]. 
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 Population Prevalence Mortality 
Low High Low High 
Afghanistan 27,208,324 41,568 117,413 3,923 17,964 
Bangladesh 160,000,128 418,373 982,401 31,463 152,003 
Brazil 191,971,504 12,407 112,628 2,714 15,249 
Cambodia 14,562,008 58,019 154,174 4,792 22,262 
China 1,337,411,200 408,980 2,203,167 64,683 329,249 
DR Congo 64,256,636 267,368 631,855 19,701 94,920 
Ethiopia 80,713,432 281,164 688,741 20,831 99,280 
India 1,181,411,968 1,044,202 3,739,672 119,082 553,196 
Indonesia 227,345,088 229,832 828,415 26,826 124,570 
Kenya 38,765,312 17,436 143,440 2,653 16,092 
Mozambique 22,382,532 64,989 159,949 3,050 16,805 
Myanmar 49,563,020 117,941 385,034 12,181 55,967 
Nigeria 151,212,256 625,992 1,299,190 33,833 181,508 
Pakistan 176,952,128 304,242 897,731 29,910 136,428 
Philippines 90,348,440 217,088 597,488 19,943 91,576 
Russian Federation 141,394,304 21,259 195,563 10,233 36,654 
South Africa 49,667,628 142,051 514,650 8,257 39,064 
Thailand 67,386,384 59,410 178,829 5,557 25,404 
Uganda 31,656,864 66,744 165,870 3,217 17,516 
UR Tanzania 42,483,924 36,198 77,478 2,601 9,395 
Viet Nam 87,095,920 121,713 419,052 12,254 62,097 
Zimbabwe 12,462,879 62,614 146,929 2,666 13,030 
 
Table 2: In 2008, 22 high TB burden countries of the world. Source: [57]. 
 
Between 1995 and 2012, about 56 million people 
were successfully treated for TB in countries that had 
adopted WHO’s global TB strategy, saving 22 
million lives. In 2011, the treatment success rate 
continued to be high at 87% among all new TB cases. 
About 75% of the estimated 2.9 million missed cases, 
people who were either not diagnosed or diagnosed 
but not reported to national tuberculosis programmes 
(NTPs), were in 12 countries (in order of total 
numbers) India (31% of the global total), South 
Africa, Bangladesh, Pakistan, Indonesia, China, 
Democratic Republic of the Congo, Mozambique, 
Nigeria, Ethiopia, the Philippines and Myanmar. By 
the end June 2013, 1,402 testing machines and 3.2 
million test cartridges had been procured by 88 of the 
145 countries eligible for concessional prices [62]. 
     A total of 94,000 TB patients eligible for MDR 
TB treatment were detected in 2012: 84,000 people 
with confirmed MDR TB and 10,000 with 
Rifampicin resistance detected using Xpert 
MTB/RIF. Just over 77,000 people with MDR TB 
were started on second-line treatment in 2012, 
equivalent to 82% of the 94,000 newly detected cases 
that were eligible for treatment globally. At least one 
case of XDR TB had been reported by 92 countries 
by the end of 2012 [61].  
     Treatment success rates for TB remain lowest in 
the European Region, where in 2011 only 72% of 
new cases were successfully treated. Of the $7‒8 
billion per year required in low and middle-income 
countries in 2014 and 2015, about two-thirds is 
needed for the detection and treatment of drug 
susceptible TB, 20% for treatment of MDR TB, 10% 
for rapid diagnostic tests and associated laboratory 
strengthening, and 5% for collaborative TB/HIV 
activities [62]. 
 
16. Progress in Declining TB 
 
    About 20 years after the WHO declaration of TB 
as a global public health emergency, major progress 
has been made towards 2015 global targets set within 
the context of the Millennium Development Goals 
(MDGs). The rate of new TB cases has been falling 
worldwide for about a decade but the rate of decline 
(2% per year) remains slow. Globally by 2012, the 
TB mortality rate had been reduced by 45% since 
1990 and the target to reduce deaths by 50% by 2015 
is within reach [62]. 
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    Between 2000 and 2013 deaths in Bangladesh 
from TB has fallen at a faster rate than the global 
average at 11.1% compared to 3.1% globally. 
Although active TB is declining but MDR TB and 
XDR TB are increasing globally. Because these 
diseases are not cured by first-line drugs of TB and 
second-line medicines of these TB are expensive and 
have serious side-effects [40]. 
    1 October 2011, The UN health agency reported 
that for the first time the number of people falling ill 
with TB each year is declining, but warned that 
current progress is at risk due to under-funding. The 
report shows that the TB death rate dropped 40% 
between 1990 and 2010, and all regions, except 
Africa. The number of new cases of TB has fallen 
and its prevalence was lower in 2010 than in 2005 in 
all the SSA. China’s TB death rate fell by about 80%, 
falling from 216,000 in 1990 to 55,000 in 2010  [44]. 
     New data published in the WHO shows that the 
number of people who fell ill with TB dropped to 8.8 
million in 2010, after peaking at 9 million in 2005. 
The report also finds that TB deaths fell to 1.4 
million in 2010, after reaching 1.8 million in 2003 
[60]. Funding in the 22 high-burden countries is 80% 
of the world’s TB cases early doubled from $1.2 
billion in 2002 to $2.2 billion in 2009. In 2009, 
available investments for TB total become about $3 
billion [45]. 
    The Global Alliance for TB Drug Development 
focuses on shortening the duration of TB therapy, 
treating MDR TB and ensuring compatibility with 
antiretroviral drugs to treat HIV. Several drugs in 
advanced stages of development may help shorten 
TB therapy from 6–8 months to 2–4 months [45].  
 
17. Research and Development 
(R&D) in TB 
 
      Research is urgently needed for better vaccines, 
diagnostics, and treatment options to protect children 
from and cure them of TB. Funding for TB R&D 
overall is dangerously inadequate in 2012 and it is 
suffering a $1.4 billion shortfall. In 2012, 85 donors 
reported investing $627.4 million to support TB 
R&D, a 4.63% decrease from the $657.8 million 
invested in 2011 and a 0.50% decrease compared 
with funding in 2010. The $627.4 million spent on 
TB R&D in 2012 represents just 31.4% of the 
recommended $2 billion annual investment. The 
keyword search yielded 14 donors in 2012, and 12 
donors in both 2010 and 2011, this methodology 
likely resulted in an underestimate of pediatric TB 
R&D funding. In 2012, reported pediatric TB R&D 
funding amounted to $10.3 million, with just 14 
donors disclosing their funding. Pediatric TB R&D 
received just 2% of the $627.4 million that 85 
funders invested in overall TB R&D in 2012 [43]. 
     The WHO has placed DR TB on the agenda of its 
67th World Health Assembly, which will take place 
on 19–24 May, 2014. After 40 years with no new TB 
drugs, a new class of TB antibiotics has recently been 
approved for market entry. There are more products 
in the pipeline from large pharmaceutical companies 
for DR TB than for non-DR TB. There are two drugs 
that target the most DR TB: Linezolid from Pfizer 
and Bedaquiline from Johnson & Johnson. 
Investment in new TB vaccine development will be a 
cost-effective approach to saving lives. Experts 
estimate that it will cost more than $24 billion for 
low- and middle-income countries to deal with this 
deadly disease through 2015 alone [64]. 
     More than 50 companies are involved in 
development of new diagnostic tests. 10 new or 
repurposed TB drugs are in late phases of clinical 
development. In late 2012, Bedaquiline became the 
first novel TB drug approved in 40 years. In June 
2013, WHO issued interim guidance for its use in 
treatment of MDR TB. There are 10 vaccines for TB 
prevention and two immunotherapeutic vaccines in 
the pipeline. In early 2013, results from a Phase IIb 
proof-of-concept study of one of the preventive 
vaccine candidates were published. While efficacy 
was not superior to the Bacille-Calmette-Guérin 
(BCG) vaccine alone, the study demonstrated that a 
trial of a novel TB vaccine is feasible in a high TB 
burden setting. Short, effective and well-tolerated 
treatments for latent TB infection, a point-of-care 
diagnostic test, and an effective post-exposure 
vaccine are needed to help end the global TB 
epidemic [62].  
      The Foundation for Innovative New Diagnostics 
(FIND) is working to develop rapid diagnostics to 
more efficiently and reliably detect TB and MDR TB. 
The Aeras Global TB Vaccine Foundation is 
supporting research into new TB vaccines, including 
working to make a modified BCG vaccine [45]. 
  
18. Recommendations 
 
      TB is a challenging disease to diagnose, treat, and 
control. In high MDR TB burden countries, increased 
capacity to diagnose MDR TB must be matched with 
supplies of quality drugs and scaled-up country 
capacity to deliver effective treatment and care. The 
top priority is needed to increase coverage of ART 
for HIV-positive TB patients towards the 100% 
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target. Fund in TB treatment must be increased 
locally and globally. 
      In some developing countries BCG reaches often 
in late when bacteria already appear in the sputum 
and are being spread to previously uninfected 
contacts. The Government of these countries must be 
active to provide BCG vaccine timely in these areas 
where TB prevalence is very high. The vaccines must 
be collected from the reputed companies and use 
before expire date. 
     Hospitals and clinics should reduce crowding, 
facilitate flow of patients and provide adequate 
ventilation to decrease TB transmission. Civil society 
and communities can create demand for TB infection 
control and help to implement it. The concentration 
of infectious respiratory aerosols i.e., droplet nuclei 
should be reduced in the air and control the direction 
of infectious air in the hospitals and TB care centers. 
     Hospitals and clinics take precautions to prevent 
the spread of TB by identifying patients with 
suspected TB and using ultraviolet light to sterilize 
the air, special filters, and special respirators and 
masks. In hospitals, people with TB are isolated in 
special rooms with controlled ventilation and airflow 
until they can no longer spread TB bacteria. Special 
care must be given in proper use of medicines to 
avoid MDR TB and XDR TB. HCPs must be 
conscious about the patients HIV-positive that are co-
infected of HIV and TB, and treat the patients 
accordingly.  
     HCPs promptly identify people with TB 
symptoms, separate the infectious patients (from 
other patients) and keep them in special rooms with 
controlled ventilation and airflow, control the spread 
of pathogens (cough etiquette and respiratory 
hygiene) and minimize time spent in healthcare 
facilities. By having an infection control plan in 
place, healthcare settings can ensure the prompt 
detection and treatment of persons who have 
suspected or confirmed TB disease. Correct diagnosis 
of TB is needed to improve treatment, reduce 
transmission, and control development of drug 
resistance. 
 
19. Concluding Remarks 
 
       In this study we have discussed the history, 
infection, diagnosis, treatment and prevention 
techniques of TB. As it is a curable and preventable 
disease, most people undergo complete healing of 
their initial infection, and the bacteria eventually die 
off if the patients find proper treatment. So that 
prevalence of TB and mortality rate can be reduced 
by the consciousness and proper treatment. Infection 
and mortality rate due to TB is very high (more than 
95%) in the developing countries. TB infections in 
the world began to increasing since 1980s, because of 
the appearance of HIV. The TB death rate has 
dropped 45% between 1990 and 2012, and about 22 
million lives are saved. DR TB is increasing globally 
due to misused or mismanaged of the required 
medicines. The patients with MDR TB and XDR TB 
have relatively higher morbidity, which are difficult 
or sometimes impossible to treat successfully. We 
have stressed on proper and regular continuous 
treatment to avoid MDR TB and XDR TB. To reduce 
or eradicate TB from the society fund in R&D in TB 
need to be increased. BCG is used in many countries 
with a high prevalence of TB to prevent childhood 
tuberculous meningitis and miliary disease. At 
present each year about 100 million children receive 
BCG vaccine worldwide. We hope in near future TB 
will be extinct from the world and human being will 
consider TB a mere painful disease of past.   
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